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Abstract
Objectives: The FlowTriever All‐Comer Registry for Patient Safety and Hemodynamics (FLASH) is a prospective multi‐center registry evaluating the safety and
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effectiveness of percutaneous mechanical thrombectomy for treatment of
pulmonary embolism (PE) in a real‐world patient population (NCT03761173). This
interim analysis reports outcomes for the first 250 patients enrolled in FLASH.

Funding information

Background: High‐ and intermediate‐risk PEs are characterized by high mortality

Inari Medical

rates, frequent readmissions, and long‐term sequelae. Mechanical thrombectomy is
emerging as a front‐line therapy for PE that enables immediate thrombus reduction
while avoiding the bleeding risks inherent with thrombolytics.
Methods: The primary endpoint is a composite of major adverse events (MAE)
including device‐related death, major bleeding, and intraprocedural device‐ or
procedure‐related adverse events at 48 h. Secondary endpoints include on‐table
changes in hemodynamics and longer‐term measures including dyspnea, heart rate,
and cardiac function.
Results: Patients were predominantly intermediate‐risk per ESC guidelines (6.8%
high‐risk, 93.2% intermediate‐risk). There were three MAEs (1.2%), all of which were
major bleeds that resolved without sequelae, with no device‐related injuries, clinical
deteriorations, or deaths at 48 h. All‐cause mortality was 0.4% at 30 days, with a
single death that was unrelated to PE. Significant on‐table improvements in hemodynamics were noted, including an average reduction in mean pulmonary artery
pressure of 7.1 mmHg (22.2%, p < 0.001). Patient symptoms and cardiac function
improved through follow‐up.
Conclusions: These interim results provide preliminary evidence of excellent safety
in a real‐world PE population. Reported outcomes suggest that mechanical thrombectomy can result in immediate hemodynamic improvements, symptom reduction,
and cardiac function recovery.
KEYWORDS

hemodynamics, mechanical thrombectomy, percutaneous intervention, pulmonary embolism
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| INTRODUCTION

thrombolytics had less hemodynamic deterioration compared to anticoagulation alone.7 These results parallel earlier thrombolytic trials

Pulmonary embolism (PE) has been characterized by high acute

which included both intermediate‐risk and high‐risk PE patients.8 The

mortality rates and unsatisfactory long‐term outcomes.1 PE re-

consistent trade‐off with thrombolytic therapy in these trials, how-

presents the third leading cause of death from cardiovascular dis-

ever, was an increased major bleeding rate of up to 10%,2,9 including

2

ease, with the clinical impact of PE predicated by the degree of

an intracerebral hemorrhage rate of up to 2%.2,8,10 Therefore, the

acute right ventricular (RV) dysfunction. Contemporary registries

need for careful consideration of thrombolysis risks versus benefits

report 30‐day mortality rates up to 30% in high‐risk PE and 15% in

has been paramount when considering advanced treatment.

3

intermediate‐risk PE. Furthermore, patients who survive the acute

The FlowTriever System (Inari Medical) is the first FDA‐cleared

episode often experience long‐term complications including pul-

mechanical thrombectomy device for the treatment of PE. The large‐

monary hypertension,1 exercise intolerance, dyspnea, and reduced

bore system combines aspiration and mechanical thrombus extrac-

quality of life.4–6

tion to obviate the need for thrombolytics and their associated

The ideal treatment for PE patients at risk for progressive de-

bleeding risk. The safety and effectiveness of FlowTriever throm-

compensation would allow for safe, rapid debulking of the pulmonary

bectomy in treating intermediate‐risk PE was first demonstrated in

arteries (PA) to improve acute right heart strain and prevent long

the FLARE trial.11 After single‐session thrombectomy, patients

term consequences of pulmonary vascular obstruction. Historically,

showed significant improvement in right ventricle/left ventricle (RV/

systemic and catheter‐directed thrombolytics have represented the

LV) ratio and a low rate of major adverse events, with only 1.9% of

dominant therapies to improve acute RV failure. In the landmark

patients receiving adjunctive thrombolytics. While these initial results

PEITHO trial, intermediate‐risk PE patients treated early with

were encouraging, the FLARE study was performed using the
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first‐generation FlowTriever System, the patient cohort was re-

2.3 |

3

Secondary endpoints

stricted to intermediate‐risk PE patients, and outcome measures
were limited to surrogate measures of clinical outcomes. Therefore,

Secondary safety endpoints include the individual components of

the FlowTriever All‐Comer Registry for Patient Safety and Hemody-

the MAE composite endpoint, major access site complications

namics (FLASH) was designed to evaluate the safety and effective-

requiring open surgical or endovascular intervention or blood

ness of the current FlowTriever System in a broader real‐world

transfusion, all‐cause mortality through 30 days, and device‐related

setting, including both intermediate‐risk and high‐risk PE patients and

serious adverse events (SAE) within 30 days. Secondary effective-

collecting direct measures of patient hemodynamic status following

ness endpoints include on‐table changes in hemodynamics and

thrombectomy as well as longer‐term clinical outcomes. This report

vitals during the procedure, as well as markers of cardiac size and

represents the first publication of results from the initial 250 patients

function at follow‐up as measured by echocardiography. The

enrolled in the FLASH registry.

baseline RV/LV ratio is a composite of computed tomography (CT)
and echocardiography assessments, with CT prioritized if both were
available. To exclude bias due to differences in imaging techniques,

2

| MATERIALS AND METHODS

the longitudinal analysis of RV/LV ratio was exclusively based on
paired echocardiography data, with the latest follow‐up prioritized if

2.1

| Study design

multiple were available.
Additional secondary endpoints include utility measures such as

FLASH is a prospective, multi‐center registry (ClinicalTrials.gov

thrombectomy time (calculated from when the Triever aspiration

identifier: NCT03761173) to evaluate real‐world outcomes in PE

catheter enters the vasculature until final removal), estimated blood

patients treated with the FlowTriever System. Investigators obtained

loss, lengths of postprocedure hospital and intensive care unit (ICU)

Institutional Review Board approval at each site before enrolling

stays, and dyspnea as measured on the modified Medical Research

patients, and all patients provided written informed consent.

Council (mMRC) dyspnea scale from 0 to 4.

Inclusion and exclusion criteria were selected to allow an assessment of the FlowTriever System in an all‐comers population to
mimic real‐world clinical practice. Inclusion criteria were patients

2.4 |

Hemodynamic calculations

over 18 years old who had clinical signs and symptoms of acute PE
with evidence of proximal filling defect in at least one main or lobar

Invasive hemodynamic assessment was performed per protocol be-

PA and who were undergoing PE treatment with the FlowTriever

fore the procedure and 5 min following removal of the Triever ca-

System per the investigator's discretion. Exclusion criteria were lim-

theter. Standard hemodynamic variables were collected, including

ited only to patients unable to be anticoagulated, known sensitivity to

right atrial pressure and systolic, diastolic, and mean PA pressures.

radiographic contrast that cannot be adequately pretreated, evidence

Other derived hemodynamic endpoints including cardiac index, total

that the patient was not an appropriate candidate for mechanical

pulmonary vascular resistance, stroke volume index, RV stroke work

thrombectomy, life expectancy less than 30 days, or current partici-

index, and PA pulsatility index were calculated using standard

pation in another investigational drug or device treatment study that

formulae.

would interfere with participation in FLASH. Enrolled patients were
classified as high‐risk or intermediate‐risk (including intermediate‐
high and intermediate‐low subclasses) according to the criteria spe-

2.5 |

Data collection and analysis

cified in the current ESC guidelines for diagnosis and management of
acute PE.12 After treatment with the FlowTriever System, follow‐up

Patients were considered to be enrolled when the FlowTriever Sys-

assessments occurred at 48 h, 30 days, and 6 months.

tem entered the vasculature, with signed informed consent allowed
before or after the procedure to provide investigators flexibility in
enrolling a real‐world PE population. This interim analysis focused on

2.2

| Primary endpoint

assessment of acute and 48‐h safety and effectiveness along with
additional longer‐term safety and clinical outcomes where available,

The primary endpoint of FLASH is a composite of major adverse

including serious adverse events, hospital readmissions, heart rate,

events (MAE) within 48 h of the index procedure consisting of

and dyspnea scores at up to 30 days and RV size and function at the

device‐related death, major bleeding, and device‐ or procedure‐

latest point available up through study exit. An independent medical

related adverse events. Major bleeding was defined based on BARC

monitor adjudicated adverse events and determined device‐ and

Type 3b or greater.13 Intraprocedural device‐ or procedure‐related

procedure‐relatedness. Data are presented either as numbers (%),

adverse events were specified as clinical deterioration defined by

mean ± standard deviation, or median [interquartile range]. p values

hemodynamic or respiratory worsening meeting specific thresholds

for hypothesis testing were calculated by Wilcoxon signed‐rank and

described in the study protocol, device‐related pulmonary vascular

McNemar's tests for continuous and categorical outcomes, respec-

injury, and device‐related cardiac injury.

tively, using available pairwise values.

4
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| Patient population

TABLE 1
acute PE

ET AL.

Baseline demographics and clinical characteristics of

Characteristic

n (%) or mean ± SD

Age (Years)

60.9 ± 13.9

Male sex

131 (52.4%)

sites. The majority of patients were male (52.4%), and the average

History of DVT

53 (21.2%)

age was 60.9 ± 13.9 years. Concomitant deep vein thrombosis (DVT)

History of PE

31 (12.4%)

was present in most patients (68.4%) and almost a quarter of patients

History of pulmonary hypertension

36 (14.5%)

Concomitant DVT

169 (68.4%)

40% had a contraindication to thrombolytics. Most (93.2%) patients

Active bleed

6 (2.4%)

had intermediate‐risk PE and 6.8% had high‐risk PE per current ESC

History of cancer

59 (23.6%)

guidelines. Most (84.3%) patients had an sPESI score ≥1. Additional

Active cancer

20 (8.0%)

Recent surgery

35 (14.0%)

Thrombolytics contraindication

100 (40.0%)

Intermediate‐risk (Submassive)

233 (93.2%)

From December 2018 to July 2020, 250 patients with acute high‐risk
(massive) or intermediate‐risk (submassive) PE were enrolled at 19 US

(23.6%) presented with a history of cancer, including 8.0% with active
cancer. Nearly 15% of patients had undergone recent surgery, and

patient demographics and PE‐relevant variables are outlined in
Table 1.

3.2

| Procedural characteristics and hospital stay

A representative FLASH case, including pulmonary angiograms and
extracted clot burden, is shown in Figure 1. The median thrombect-

Intermediate‐high

200 (85.8%)

Intermediate‐low

15 (6.4%)

Unclassified

18 (7.7%)

omy time reported was 46.0 [29.0–70.0] min, and the median esti-

High‐risk (massive)

17 (6.8%)

mated blood loss was 255.0 [100.0–425.0] ml. Twelve patients (4.8%)

sPESI

1.6 ± 1.1

were given adjunctive therapy, including 11 patients (4.4%) who received thrombolytics. There was only one (0.4%) access site complication, a hematoma which occurred in a patient who had received

0

37 (15.7%)

≥1

198 (84.3%)

intraprocedural thrombolytics. Most patients (56.8%) did not require

Positive biomarkers (troponin and/or BNP)

226 (96.2%)

an ICU stay following thrombectomy. Further procedural results are

RV/LV ratio (CT or echocardiogram)

1.5 ± 0.5

Saddle PE

97 (38.8%)

Unilateral PE

29 (11.6%)

Bilateral PE

124 (49.6%)

shown in Table 2.

3.3

| Primary endpoint and safety

Note: Numbers vary from 233 to 250 patients for the different variables.

The major safety outcomes are outlined in Table 3. Within 48 h
postprocedure, MAEs included in the primary endpoint occurred in
3 (1.2%) patients, all of which were considered SAEs but none of
which were device‐related or involved intracerebral hemorrhage. All

Abbreviations: numbers (n), standard deviation (SD), deep vein thrombosis
(DVT), pulmonary embolism (PE), simplified pulmonary embolism severity
index (sPESI), B‐type natriuretic peptide (BNP), right ventricle (RV),
left ventricle (LV), computed tomography (CT).

three MAEs were major bleeds that occurred in patients who recently
underwent other interventions or received thrombolytics. All three

3.4 |

Acute hemodynamics and vitals

patients recovered following a transfusion of two units of blood
without further sequelae. There were no other intraprocedural

A summary of acute changes in hemodynamics and vitals is shown in

device‐ or procedure‐related adverse events, including no clinical

Table 5. In all 248 patients with mean PA pressures available pre‐ and

deteriorations, device‐related pulmonary vascular injuries, or device‐

post‐thrombectomy, mean PA pressures improved significantly by

related cardiac injuries. There were also no patient deaths (0.0%)

7.1 mmHg on average (22.2%, p < 0.001) from 31.9 ± 8.3 mmHg to

at 48 h.

24.8 ± 8.6 mmHg (Figure 2). Furthermore, in the subset of patients

Among 242 patients with 30‐day safety data available, there

with evidence of pulmonary hypertension at baseline (mean PA

was one patient death (0.4%) through 30 days, an 80‐year‐old

pressure ≥25 mmHg; n = 199, 80.2%), there was also a significant on‐

woman who experienced septic shock and ischemic bowel 12 days

table reduction in mean PA pressure of 7.6 mmHg (22.0%, p < 0.001)

postprocedure. In addition to the three MAEs, there were 12 other

from 34.6 ± 7.0 mmHg to 27.0 ± 8.0 mmHg. In all 202 patients with

non‐device‐related SAEs reported through 30 days, each of which

cardiac index (CI) available pre‐ and post‐thrombectomy, there

occurred in a single patient. A list of adjudicated SAEs is provided in

was no significant change in CI (2.7 ± 1.0 vs. 2.8 ± 1.7 l/min/m2

Table 4.

(p = 0.881)). However, in the subset of patients with a low baseline CI

TOMA
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F I G U R E 1 Representative FLASH case of a high‐risk PE patient treated with the FlowTriever System. Pre‐thrombectomy pulmonary
angiograms showed filling defects in the right (A) and left (B) PAs which resolved following treatment in (C) and (D). Extracted thrombus is shown
in (E). Case images provided by Dr. Hriday Shah (St. Joseph Mercy, Ann Arbor, MI). PA, pulmonary arteries; PE, pulmonary embolism [Color figure
can be viewed at wileyonlinelibrary.com]

TABLE 2

Procedural characteristics

Characteristic

n (%) or median [IQR]

Access site

Femoral: 247 (98.8%)
Jugular: 3 (1.2%)

Access site complications

1 (0.4%)

Thrombectomy time (min)

46.0 [29.0–70.0]

Estimated blood loss (ml)

255.0 [100.0–425.0]

Patients receiving adjunctive therapy

12 (4.8%)

Hospital length of stay (days
postprocedure)

3.0 [2.0–5.0]

ICU length of stay (days postprocedure)

0.0 [0.0–1.0]

Patients in ICU (postprocedure)

108 (43.2%)

T A B L E 3 Safety endpoints following treatment with the
FlowTriever System
Safety endpoints

n (%)

48‐h all‐cause mortality

0 (0%)

30‐day all‐cause mortality

1 (0.4%)

48‐h MAE composite

3 (1.2%)

Device‐related death

0 (0%)

Major bleeds (none were intracerebral hemorrhages)

3 (1.2%)

Intraprocedural device‐ or procedure‐related adverse
events

0 (0%)

Clinical deterioration

0 (0%)

Device‐related pulmonary vascular injuries

0 (0%)

Device‐related cardiac injuries

0 (0%)

Note: Numbers vary from 220 to 250 patients for the different variables.
Abbreviations: ICU, intensive care unit; IQR, interquartile range; n,
numbers.

(<2.0 l/min/m2; n = 42, 20.8%), CI significantly improved by 13.3%

30‐day SAE (device‐related)

0 (0%)

Note: Numbers vary from 247 for 48‐h data to 242 for 30‐day data.
Abbreviations: numbers (n), major adverse events (MAE), serious adverse
events (SAE).

on‐table from 1.7 ± 0.2 to 1.9 ± 0.4 l/min/m2 (p = 0.005). The overall
decrease in PA pressure and increased cardiac output resulted in a

pre‐procedure to 17.2% during postprocedure in‐hospital monitoring

significant decrease in the total pulmonary vascular resistance from

(p < 0.001) and to 11.3% at 30 days (p < 0.001).

6.1 ± 2.5 to 4.6 ± 2.0 Wood units (p < 0.001).
Heart rate significantly decreased during hospitalization by 13.5
bpm on average (12.6%, p < 0.001) from a pre‐procedure average of

3.5 |

Dyspnea scores

101.4 ± 15.0 bpm to a postprocedure average of 87.9 ± 13.3 bpm.
Heart rate continued to significantly improve at 30 days

Among patients who were dyspneic before thrombectomy (score > 0

(80.7 ± 14.6 bpm, p < 0.001) compared to the in‐hospital pre‐

on the mMRC scale), dyspnea scores decreased significantly from

procedure average (Figure 3). There was also a significant decrease in

2.9 ± 1.1 preprocedure to 1.4 ± 1.3 at 48 h (p < 0.001). The average

the percentage of tachycardic (>100 bpm) patients from 49.2%

dyspnea score showed further significant improvement to 0.8 ± 1.1 at

6
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to the patient's acute PE, involving a patient who had experienced
minor hemoptysis during the procedure and was re‐admitted
for another occurrence of hemoptysis which resolved without

Preferred MedDRA term

Device‐related?

Number of
occurrences

Anemia

No

1

Bradycardia

No

1

Cardiac failure

No

1

Cerebrovascular accident

No

1

Interim results from the first 250 patients enrolled in the FLASH

Deep vein thrombosis

No

1

registry

Hemoptysis

No

1

Hypotension

No

1

Hypovolemic shock

No

1

a low 1.2% MAE rate and no deaths through 48 h. At 30 days,

Intestinal perforation

No

1

mortality and incidence of serious adverse events remained low,

Retroperitoneal hematoma

No

1

Shock hemorrhagic

No

1

Ventricular tachycardia

No

1

sequelae.

4 |

D IS CU SS IO N

indicate

that

mechanical

thrombectomy

with

the

FlowTriever System acutely improves clinically relevant hemodynamic parameters in high‐risk and intermediate‐risk PE patients.
Safety outcomes in this real‐world population were favorable, with

while patients showed continuous improvement in heart rate and
dyspnea. RV size and function also showed improvement through

Note: These events do not include the three MAEs reported in the primary
endpoint results, all of which were also SAEs.
Abbreviations: MAE, major adverse event; MedDRA, Medical Dictionary
for Regulatory Activities; SAE, serious adverse event.

the latest follow‐up in those patients who had paired assessments
available.
Though a current limitation of this technology is the potential
blood loss associated with aspiration thrombectomy, which may be
clinically relevant in patients with anemia at baseline or low filling
pressures, the low rate of major bleeding events (1.2%) reported is
encouraging as it is similar to that observed with anticoagulation

30 days (p < 0.001) in patients with paired assessments, with an

alone in randomized trials7 and registries.3,14 Moreover, although

86.4% reduction in the percentage of patients with a dyspnea score

the FlowTriever System is a large‐bore system, a low access site

of 3 or 4 as compared to pre‐procedure (Figure 3).

complication rate of 0.4% was observed and no device‐related
cardiac or pulmonary injuries or clinical deteriorations were
reported.

3.6

| RV size and function

The patient population studied in FLASH was notably sicker than
previous thrombectomy studies,11,15 with 6.8% of patients having

RV size and function were assessed using multiple echocardiographic

high‐risk PE and the large majority of remaining patients having

variables at follow‐up times ranging from 48 h to 6 months after

intermediate‐high‐risk PE (85.8%). Furthermore, 40.0% of patients

thrombectomy. Each patient's latest follow‐up measurement was

were contraindicated for thrombolytic therapy, a patient population

prioritized if more than one was available, with the median follow‐up

commonly excluded from PE trials due to increased bleeding risk.

time ranging between 32.0 and 33.5 days depending on the variable.

Nearly 25% of patients in this study had a history of cancer, 8.0% had

In 86 patients with paired measurements, the mean RV/LV ratio

active cancer, 14.0% had recent surgery, and 68.4% had concomitant

normalized at follow‐up, significantly decreasing by 0.36 ± 0.76

DVT, a known predictor of mortality.12 Despite the elevated risk

(28.3%) from 1.27 ± 0.26 pre‐procedure to 0.91 ± 0.75 at follow‐up

profile of the real‐world patients enrolled in FLASH, there were no

(p < 0.001). In 61 patients with paired measurements, RV systolic

patient deaths through 48 h and only one mortality (0.4%) through 30

pressure also significantly decreased by 19.1 ± 15.6 mmHg (35.8%)

days. The mortality rate in FLASH compares favorably to data from

from 53.3 ± 14.2 mmHg pre‐procedure to 33.5 ± 11.9 mmHg at

the national PERT registry, which shows 30‐day mortality in acute PE

follow‐up (p < 0.001). RV systolic dysfunction and dilatation also

patients of up to 30% in high‐risk PE patients and up to 15% for

significantly improved (p < 0.001), with 90.9% of patients having no

intermediate‐risk PE patients.3

or mild RV systolic dysfunction and 84.2% having no or mild RV

While consensus is still developing among interventionalists

dilatation at follow‐up. All available data for RV size and function

regarding which specific clinical indications should prompt the

improvements are summarized in Figure 4.

use of mechanical thrombectomy for PE, the patient profile in
this study suggests that large clot burden (saddle or bilateral
PE present in 88.4% of patients), elevated cardiac biomarkers

3.7

| 30‐day readmissions

(present in 96.2% of patients), and elevated RV/LV ratio (1.5 ± 0.5)
may be factors influencing the decision to pursue mechanical

A total of 13/216 (6.0%) patients were readmitted to the hospital

thrombectomy to rapidly remove thrombus and normalize RV

through 30 days. Only one (0.5%) of these readmissions was related

function.

TOMA
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T A B L E 5 On‐table changes in
hemodynamics and vitals following
treatment with the FlowTriever System

Pre‐FT
(mean ± SD)

Post‐FT
(mean ± SD)

Difference
(% change)

Systolic PA pressure (mmHg)

51.9 ± 12.4
n = 248

39.8 ± 12.8
n = 246

−12.3 (−23.7%)
n = 245

<0.001

Mean PA pressure (mmHg)

31.9 ± 8.3
n = 249

24.8 ± 8.6
n = 248

−7.1 (−22.2%)
n = 248

<0.001

Mean PA pressure
(baseline ≥ 25 mmHg)

34.6 ± 7.0
n = 200

27.0 ± 8.0
n = 199

−7.6 (−22.0%)
n = 199

<0.001

Mean PA pressure
(baseline < 25 mmHg)

21.1 ± 2.8
n = 49

16.1 ± 4.3
n = 49

−5.1 (−22.8%)
n = 49

<0.001

Right atrial pressure (mmHg)

11.1 ± 5.9
n = 229

8.9 ± 5.5
n = 208

−2.3 (−18.1%)
n = 206

<0.001

Heart rate (bpm)

101.4 ± 15.0
n = 250

87.9 ± 13.3
n = 250

−13.5 (−12.6%)
n = 250

<0.001

Systolic blood pressure (mmHg)

126.3 ± 20.8
n = 248

124.8 ± 22.5
n = 247

−1.7 (−0.5%)
n = 247

0.185

CI (l/min/m2)

2.7 ± 1.0
n = 220

2.8 ± 1.7
n = 207

0.1 (3.9%)
n = 202

0.881

CI (baseline < 2.0 l/min/m2)

1.7 ± 0.2
n = 47

1.9 ± 0.4
n = 42

0.2 (13.3%)
n = 42

0.005

CI (baseline ≥ 2.0 l/min/m2)

2.9 ± 0.9
n = 173

3.0 ± 1.9
n = 160

0.0 (1.4%)
n = 160

0.207

Total pulmonary vascular
resistance (mmHg/l/min)

6.1 ± 2.5
n = 220

4.6 ± 2.0
n = 207

−1.5 (−20.4%)
n = 202

Stroke volume index
(baseline < 33 ml/m2/beat)

23.5 ± 5.6
n = 147

25.9 ± 7.9
n = 134

2.3 (12.0%)
n = 134

RV stroke work index (g·m/m2)

8.4 ± 4.9
n = 208

7.0 ± 8.3
n = 184

−1.3 (−15.5%)
n = 178

PA pulsatility index

4.0 ± 4.6
n = 225

4.6 ± 5.8
n = 201

0.7 (14.4%)
n = 199

Hemodynamic/vital value

7

p value

<0.001

0.001

<0.001

0.816

Note: All hemodynamic values, with the exception of heart rate, were assessed on‐table, immediately
before and after the procedure. Heart rate was assessed as the in‐hospital pre‐procedure average and
the in‐hospital postprocedure average. Mean PA pressure is reported separately in patients with
elevated baseline values, physiologically normal baseline values, and in all patients with data. CI is
reported separately in patients with low baseline values, physiologically normal baseline values, and in
all patients with data. Stroke volume index is exclusively reported in patients with low baseline values.
All p values are based on available paired assessments using Wilcoxon signed‐rank tests.
Abbreviations: bpm, beats per minute; CI, cardiac index; FT, FlowTriever; PA, pulmonary artery; RV,
right ventricular; SD, standard deviation.

In this analysis, FlowTriever thrombectomy resulted in significant

thrombolysis at the completion of the drug infusion,16,17 a key

on‐table decreases in both mean and systolic PA pressures and total

difference in the FLASH data is that these improvements were

pulmonary vascular resistance. RV size and function showed evi-

achieved much more quickly on‐table and without the associated

dence of recovery in those patients who had paired assessments

bleeding risk of thrombolytics. Even with newer generation hybrid

available, and a favorable impact on CI was observed in patients

catheter‐directed thrombolysis technology, the improvement in PA

with low pre‐procedure CI. Interestingly, while only 6.8% of

pressure and cardiac output is negligible at the completion of

patients were categorized as having high‐risk PE, 21.4% of patients in

the procedure.18

whom pre‐procedure CI was measured presented with a pre‐

In addition to providing evidence supporting the safety and

2

procedure CI below 2.0 l/min/m , indicating that some seemingly

effectiveness of the FlowTriever System in real‐world PE patients,

stable patients have significant hemodynamic compromise, similar to

these interim results also suggest the ability of mechanical throm-

prior reports.16 While the hemodynamic improvements observed in

bectomy to reduce hospital resource use in the treatment of acute

the FLASH registry are similar to data reported for catheter‐directed

PE. Most patients were able to avoid the ICU postprocedure and had

8
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F I G U R E 2 On‐table hemodynamic improvements. (A) Mean PA pressure, (B) total pulmonary vascular resistance, and (C) cardiac index in
patients with baseline values below 2.0 l/min/m2 were all significantly improved immediately following FlowTriever thrombectomy. CI, cardiac
index; FT, FlowTriever; PA, pulmonary artery; TPVR, total pulmonary vascular resistance. All p values are based on available paired assessments
using Wilcoxon signed‐rank tests [Color figure can be viewed at wileyonlinelibrary.com]

F I G U R E 3 Heart rate and dyspnea improvements through 30 days. (A) Heart rate is reported as the in‐hospital pre‐procedure average
(“Pre‐FT”), the in‐hospital post‐procedure average (“Post‐FT”), and the value at the 30‐day visit (“30d”). p values are based on Wilcoxon signed‐
rank tests for follow‐up values paired with Pre‐FT values. (B) Dyspnea severity is reported for patients who were dyspneic before treatment,
showing dyspnea scores pre‐procedure and at 48 h and 30 days postprocedure based on the modified Medical Research Council (mMRC)
dyspnea scale. BPM, beats per minute; FT, FlowTriever [Color figure can be viewed at wileyonlinelibrary.com]

shorter hospital stays than previously reported, with a median hos-

the need to schedule multiple procedures in the angiography suite,

pital stay of 3.0 days postprocedure as compared to a mean 8.8 days

and the 30‐day readmission rate was low (6.0%), with only one

17

in SEATTLE II.

The ICU benefit was largely due to lack of throm-

patient being readmitted to the hospital for a cause related to the

bolytic infusions, but it also points to the fact that most patients

acute PE or treatment. This readmission rate in particular compares

had on‐table hemodynamic improvements and were less critical

favorably to the nearly 20% readmission rate cited in the literature

postprocedure. All patients were treated in a single session, avoiding

for venous thromboembolism and PE patients.14,19

TOMA
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F I G U R E 4 Improved RV size and function assessed via echocardiography. (A) Mean RV/LV ratio, (B) mean RV systolic pressure, (C) RV
systolic dysfunction grades, and (D) RV dilatation grades each showed significant improvement at follow‐up, which represents a composite of
the latest assessment available for each subject. Median follow‐up time was 32.0–33.5 days, depending on the variable. In (A) and (B), all
available preprocedure and follow‐up data are shown, though statistical comparisons are limited to patients with paired assessments (RV/LV
ratio: n = 86 with mean difference of −0.36; RV systolic pressure: n = 61 with mean difference of −19.1 mmHg). p values are calculated from
Wilcoxon signed‐rank tests. FT, FlowTriever; LV, left ventricle; RV, right ventricle [Color figure can be viewed at wileyonlinelibrary.com]

4.1

| Study limitations

sites follow established workflows for their PE patients which may
involve ICU stays and adjunctive therapies, including thrombolytics.

There are several limitations of this interim registry analysis, the
primary of which is the lack of a comparator arm. Though a comparator arm is not part of the FLASH registry design, the next phase

5 |

CONCLUSION

of the registry will include the addition of a contextual arm for
patients who receive anticoagulation alone. Given the practical lim-

The FLASH registry is designed to study a broad range of acute and

itations of consenting some PE patients, especially those unable to

longer‐term outcomes in a real‐world PE patient population following

sign informed consent before treatment, the outcomes reported may

mechanical thrombectomy with the FlowTriever System. Primary

be impacted by selection bias. A minority of patients (6%) had

results from the first 250 patients enrolled in FLASH underscore the

intermediate‐low risk for mortality when risk‐stratified using main-

favorable safety profile of FlowTriever thrombectomy, with 0.4%

stay clinical guidelines.12 The inclusion of these intermediate‐low‐risk

all‐cause mortality within 30 days in an intermediate‐ and high‐risk

patients in this interim analysis may have slightly insulated the overall

patient population. In addition, these data suggest that FlowTriever

safety profile and mortality rate, though any potential skewing effect

thrombectomy can result in significant immediate improvements in

is expected to be minimal due to the low numbers of intermediate‐

hemodynamics as well as dyspnea resolution and cardiac function

low‐risk patients enrolled. In addition, most of the present analysis is

recovery. Further data collection out to 6 months will provide

limited to 30‐day follow‐up, tempering what conclusions can be

additional insights on safety and effectiveness of mechanical

drawn about longer‐term outcomes in these patients. This limitation

thrombectomy as a frontline therapy for PE and provide a platform

will be addressed with longer‐term follow‐up and additional func-

for designing future definitive studies.

tional data collection as the registry continues, which will allow further assessment of the clinical benefits of FlowTriever thrombectomy
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